One-of-a-kind protection

The only vaccine licensed to protect against inflammation and pathology of subclinical arthritis and its potential long-term repercussions1,5

NOBIVAC® LYME PROVIDES PROVEN PROTECTION FOR CANINES

Our commitment to leadership is vaccine development that provides comprehensive protection against Lyme disease.

PRODUCT LABEL
  • Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection
  • Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi 1,5
  • Proven to help prevent clinical disease such as arthritis – as well as at the subclinical level 5
  • Highly effective: no serologic evidence of exposure to Borrelia burgdorferi 5

INDICATIONS:

Shown to be effective for vaccination of healthy dogs 8 weeks of age or older against Borrelia burgdorferi. Duration of Immunity is at least 1 year. Also been shown to be effective against subclinical arthritis caused by Borrelia burgdorferi. Recommended for use in healthy dogs 8 weeks of age or older.

NOBIVAC® LYME IS A SAFE CHOICE

  • Proven safe and well tolerated in a field safety trial of more than 600 dogs
  • 99.3% reaction-free
  • Since 2009, Nobivac® Lyme has been safely administered to over 4 million dogs

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Two 1 mL doses given 2 to 4 weeks apart
  • Duration of immunity is at least 1 year
  • Available in a 25 x 1 mL dose presentation

DISEASE INFORMATION

  • Canine Lyme Disease

Efficacy

ANTIBODY ACTIVITY

THE BORRELIACIDAL DIFFERENCE

Only Nobivac® Lyme induces borreliacidal activity against both OspA and OspC1,5,80 Not all antibody responses are the same.

  • “Multi-Osp protection” that induces antibodies against Osps other than OspA and OspC has not been shown to be relevant5,29,30
  • Other Lyme vaccines may induce antibodies against OspC, but they are not borreliacidal—meaning they don’t kill Borrelia burgdorferi
    • As a result, vaccines that only induce borreliacidal antibodies against OspA provide incomplete protection once OspC becomes the dominant protein expressed in the tick
  • Only Nobivac® Lyme induces OspC borreliacidal antibodies that kill spirochetes in the tick midgut, those migrating from the midgut to the tick’s salivary glands, and those introduced into the dog80

COMPETITIVE COMPARISON

ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.

PREVENTS JOINT ABNORMALITIES

NOBIVAC® LYME IS SHOWN TO BE EFFECTIVE AGAINST SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE5

Following vaccination with Nobivac® Lyme:

  • No Borrelia burgdorferi were found in the joint
  • No joint inflammation, stiffness, or lameness were observed5
    • 40% of control dogs developed chronic joint inflammation5
    • 27% of control dogs developed joint stiffness or lameness5
  • Dogs exhibited no signs of Lyme disease–associated joint abnormalities5

TICK CHALLENGE STUDY

NOBIVAC® LYME IS HIGHLY EFFECTIVE IN KILLING BORRELIA BURGDORFERI AND PREVENTING INFECTION5

Tick challenge study confirms effectiveness.5

Following vaccination with Nobivac® Lyme, no B. burgdorferi were found.

The tick challenge study was a placebo-controlled trial involving thirty 8-week-old puppies. Dogs were challenged 3 weeks following second vaccination.

No items to show.

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

Lyme Disease Pet Parent Guide

Brochure

Printable brochure to educate pet parents about their dog’s risk for Canine Lyme Disease.

What is Lyme disease?

What are the signs of Lyme disease?

How serious is Lyme disease?

Download

No items to show.

View More Nobivac® Resources

References:

View All Nobivac References